speb/financial-data huggingface dataset:
MRN.PA cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -3200000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Net Debt: 309900000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Net Debt: 309900000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income: 14100000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 14100000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 12800000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 14100000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 14100000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 30500000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 12800000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -13400000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Interest Income: -26000000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 57800000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 57800000.00
MRN.PA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -26000000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 100000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 500000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Net PPE: 764700000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Net PPE: 764700000.00
MRN.PA cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -129300000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 436300000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 436300000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 20300000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 20300000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 52700000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 52700000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 25000000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 25000000.00
MRN.PA income_statement (annual, 2025-12-31) — Normalized EBITDA: 186100000.00
MRN.PA income_statement (annual, 2025-12-31) — Normalized Income: 53475000.00
MRN.PA cash_flow (annual, 2025-12-31) — Operating Cash Flow: 186000000.00
MRN.PA income_statement (annual, 2025-12-31) — Operating Income: 109100000.00
MRN.PA income_statement (annual, 2025-12-31) — Operating Revenue: 1186400000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 24346098.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 24346098.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 9100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 9100000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 66900000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 66900000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Inventories: 100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Inventories: 100000.00
MRN.PA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 27800000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 100000.00
MRN.PA income_statement (annual, 2025-12-31) — Other Operating Expenses: 1800000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Payable: 116800000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Payable: 116800000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Properties: 103200000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Properties: 103200000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Receivables: 37100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Receivables: 37100000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 8100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 8100000.00
MRN.PA income_statement (annual, 2025-12-31) — Other Special Charges: 9800000.00
MRN.PA income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
MRN.PA balance_sheet (annual, 2025-12-31) — Payables: 195800000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Payables: 195800000.00
MRN.PA income_statement (annual, 2025-12-31) — Pretax Income: 30500000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Properties: 0.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
MRN.PA cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: -3800000.00
MRN.PA cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -13400000.00
MRN.PA cash_flow (annual, 2025-12-31) — Purchase Of PPE: -129300000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Raw Materials: 144000000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Raw Materials: 144000000.00
MRN.PA income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 834700000.00
MRN.PA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 81300000.00
MRN.PA cash_flow (annual, 2025-12-31) — Repayment Of Debt: -253200000.00
MRN.PA income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: -2000000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Retained Earnings: 14100000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 14100000.00
MRN.PA income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 83200000.00
MRN.PA income_statement (annual, 2025-12-31) — Selling General And Administration: 238900000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Share Issued: 24418312.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Share Issued: 24418312.00
MRN.PA income_statement (annual, 2025-12-31) — Special Income Charges: -52500000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 782800000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 782800000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 436300000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 436300000.00
MRN.PA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -13125000.00
MRN.PA income_statement (annual, 2025-12-31) — Tax Provision: 17800000.00
MRN.PA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.25
MRN.PA balance_sheet (annual, 2025-12-31) — Taxes Receivable: 4400000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 4400000.00
MRN.PA cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -9800000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Assets: 1703200000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Assets: 1703200000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Capitalization: 1172400000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1172400000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Debt: 453700000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Debt: 453700000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 807200000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 807200000.00
MRN.PA income_statement (annual, 2025-12-31) — Total Expenses: 1077300000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 896000000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 896000000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 1145600000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 1145600000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 517700000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 517700000.00
MRN.PA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 56300000.00
MRN.PA income_statement (annual, 2025-12-31) — Total Other Finance Cost: 4200000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Total Tax Payable: 5600000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 5600000.00
MRN.PA income_statement (annual, 2025-12-31) — Total Unusual Items: -52500000.00
MRN.PA income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -52500000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 72214.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 72214.00
MRN.PA balance_sheet (annual, 2025-12-31) — Work In Process: 77400000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Work In Process: 77400000.00
MRN.PA balance_sheet (annual, 2025-12-31) — Working Capital: 179200000.00
MRN.PA balance_sheet (quarterly, 2025-12-31) — Working Capital: 179200000.00
MRN.PA income_statement (annual, 2025-12-31) — Write Off: 44700000.00
MRNA income_statement (annual, 2021-12-31) — Basic Average Shares: 403000000.00
MRNA income_statement (annual, 2021-12-31) — Basic EPS: 30.31
MRNA cash_flow (annual, 2021-12-31) — Change In Income Tax Payable: 876000000.00
MRNA cash_flow (annual, 2021-12-31) — Change In Tax Payable: 876000000.00
MRNA cash_flow (annual, 2021-12-31) — Common Stock Payments: -857000000.00
MRNA cash_flow (annual, 2021-12-31) — Deferred Income Tax: -318000000.00
MRNA cash_flow (annual, 2021-12-31) — Deferred Tax: -318000000.00
MRNA income_statement (annual, 2021-12-31) — Diluted Average Shares: 431000000.00
MRNA income_statement (annual, 2021-12-31) — Diluted EPS: 28.29
MRNA balance_sheet (annual, 2021-12-31) — Hedging Assets Current: 21000000.00
MRNA cash_flow (annual, 2021-12-31) — Income Tax Paid Supplemental Data: 480000000.00
MRNA balance_sheet (annual, 2021-12-31) — Income Tax Payable: 876000000.00
MRNA cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -140000000.00
MRNA cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -30000000.00
MRNA balance_sheet (annual, 2021-12-31) — Notes Receivable: 0.00
MRNA cash_flow (annual, 2021-12-31) — Proceeds From Stock Option Exercised: 124000000.00
MRNA cash_flow (annual, 2021-12-31) — Repayment Of Debt: -140000000.00
MRNA cash_flow (annual, 2021-12-31) — Repurchase Of Capital Stock: -857000000.00
MRNA balance_sheet (annual, 2021-12-31) — Total Tax Payable: 876000000.00
MRNA income_statement (annual, 2022-12-31) — +Operating Expense: 4039000000.00
MRNA income_statement (annual, 2022-12-31) — +Total Revenue: 18875000000.00
MRNA balance_sheet (annual, 2022-12-31) — Accounts Payable: 487000000.00
MRNA balance_sheet (annual, 2022-12-31) — Accounts Receivable: 1385000000.00
MRNA balance_sheet (annual, 2022-12-31) — Accrued Interest Receivable: 61000000.00
MRNA balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -658000000.00
MRNA balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 1173000000.00
MRNA balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: 0.00
MRNA cash_flow (annual, 2022-12-31) — Amortization Of Securities: 31000000.00
MRNA balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 8318000000.00
MRNA income_statement (annual, 2022-12-31) — Basic Average Shares: 394000000.00
MRNA income_statement (annual, 2022-12-31) — Basic EPS: 21.26
MRNA cash_flow (annual, 2022-12-31) — Beginning Cash Position: 6860000000.00
MRNA cash_flow (annual, 2022-12-31) — Capital Expenditure: -400000000.00
MRNA balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1200000000.00
MRNA balance_sheet (annual, 2022-12-31) — Capital Stock: 0.00
MRNA balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 3205000000.00
MRNA balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 9902000000.00
MRNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -3448000000.00
MRNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -5176000000.00
MRNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 4981000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Account Payable: 240000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 612000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Income Tax Payable: -828000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Inventory: 492000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 21000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -754000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -4157000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Payable: 240000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 852000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -2258000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Receivables: 1790000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Tax Payable: -828000000.00
MRNA cash_flow (annual, 2022-12-31) — Change In Working Capital: -4014000000.00
MRNA cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 1790000000.00
MRNA cash_flow (annual, 2022-12-31) — Changes In Cash: -3643000000.00
MRNA balance_sheet (annual, 2022-12-31) — Common Stock: 0.00
MRNA balance_sheet (annual, 2022-12-31) — Common Stock Equity: 19123000000.00
MRNA cash_flow (annual, 2022-12-31) — Common Stock Issuance: 65000000.00
MRNA cash_flow (annual, 2022-12-31) — Common Stock Payments: -3329000000.00
MRNA balance_sheet (annual, 2022-12-31) — Construction In Progress: 281000000.00
MRNA income_statement (annual, 2022-12-31) — Cost Of Revenue: 5416000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 1911000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Assets: 13431000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 196000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 196000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 2038000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 2038000000.00
MRNA balance_sheet (annual, 2022-12-31) — Current Liabilities: 4923000000.00
MRNA cash_flow (annual, 2022-12-31) — Deferred Income Tax: -559000000.00
MRNA cash_flow (annual, 2022-12-31) — Deferred Tax: -559000000.00
MRNA cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 348000000.00
MRNA cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 348000000.00
MRNA income_statement (annual, 2022-12-31) — Diluted Average Shares: 416000000.00
MRNA income_statement (annual, 2022-12-31) — Diluted EPS: 20.12
MRNA income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — EBIT: 9420000000.00
MRNA income_statement (annual, 2022-12-31) — EBITDA: 9768000000.00
MRNA cash_flow (annual, 2022-12-31) — Earnings Losses From Equity Investments: 0.00
MRNA cash_flow (annual, 2022-12-31) — End Cash Position: 3217000000.00
MRNA cash_flow (annual, 2022-12-31) — Financing Cash Flow: -3448000000.00
MRNA balance_sheet (annual, 2022-12-31) — Finished Goods: 169000000.00
MRNA cash_flow (annual, 2022-12-31) — Free Cash Flow: 4581000000.00
MRNA income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -20000000.00
MRNA balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -370000000.00
MRNA balance_sheet (annual, 2022-12-31) — Goodwill: 0.00
MRNA balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 0.00
MRNA balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 1385000000.00
MRNA balance_sheet (annual, 2022-12-31) — Gross PPE: 2797000000.00
MRNA income_statement (annual, 2022-12-31) — Gross Profit: 13459000000.00
MRNA cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 2729000000.00
MRNA balance_sheet (annual, 2022-12-31) — Income Tax Payable: 48000000.00
MRNA income_statement (annual, 2022-12-31) — Interest Expense: 29000000.00
MRNA income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 29000000.00
MRNA income_statement (annual, 2022-12-31) — Interest Income: 200000000.00
MRNA income_statement (annual, 2022-12-31) — Interest Income Non Operating: 200000000.00
MRNA cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 25000000.00
MRNA balance_sheet (annual, 2022-12-31) — Inventory: 949000000.00
MRNA balance_sheet (annual, 2022-12-31) — Invested Capital: 19123000000.00
MRNA cash_flow (annual, 2022-12-31) — Investing Cash Flow: -5176000000.00
MRNA balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 8318000000.00
MRNA balance_sheet (annual, 2022-12-31) — Investments And Advances: 8360000000.00
MRNA cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 65000000.00
MRNA balance_sheet (annual, 2022-12-31) — Land And Improvements: 11000000.00
MRNA balance_sheet (annual, 2022-12-31) — Leases: 460000000.00
MRNA balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 1004000000.00
MRNA balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 1004000000.00
MRNA balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 42000000.00
MRNA balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 59000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
MRNA cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -3264000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 8362000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 8362000000.00
MRNA income_statement (annual, 2022-12-31) — Net Interest Income: 200000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -4736000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -184000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -184000000.00
MRNA income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 200000000.00
MRNA cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -40000000.00
MRNA balance_sheet (annual, 2022-12-31) — Net PPE: 2139000000.00
MRNA cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -400000000.00
MRNA balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 19123000000.00
MRNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 982000000.00
MRNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 673000000.00
MRNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 673000000.00
MRNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 982000000.00
MRNA balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 0.00
MRNA income_statement (annual, 2022-12-31) — Normalized EBITDA: 9768000000.00
MRNA income_statement (annual, 2022-12-31) — Normalized Income: 8362000000.00
MRNA balance_sheet (annual, 2022-12-31) — Notes Receivable: 36000000.00
MRNA cash_flow (annual, 2022-12-31) — Operating Cash Flow: 4981000000.00
MRNA income_statement (annual, 2022-12-31) — Operating Income: 9420000000.00
MRNA income_statement (annual, 2022-12-31) — Operating Revenue: 18435000000.00
MRNA balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 385000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Current Assets: 44000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 53000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -370000000.00
MRNA income_statement (annual, 2022-12-31) — Other Income Expense: -45000000.00
MRNA cash_flow (annual, 2022-12-31) — Other Non Cash Items: 28000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 946000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 135000000.00
MRNA income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -45000000.00
MRNA income_statement (annual, 2022-12-31) — Other Operating Expenses: -388000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Properties: 1986000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Receivables: 53000000.00
MRNA balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 6697000000.00
MRNA balance_sheet (annual, 2022-12-31) — Payables: 535000000.00
MRNA balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 2446000000.00
MRNA balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 190000000.00
MRNA balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
MRNA balance_sheet (annual, 2022-12-31) — Prepaid Assets: 851000000.00
MRNA income_statement (annual, 2022-12-31) — Pretax Income: 9575000000.00
MRNA cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 65000000.00
MRNA balance_sheet (annual, 2022-12-31) — Properties: 0.00
MRNA cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
MRNA cash_flow (annual, 2022-12-31) — Purchase Of Investment: -11435000000.00
MRNA cash_flow (annual, 2022-12-31) — Purchase Of PPE: -400000000.00
MRNA balance_sheet (annual, 2022-12-31) — Raw Materials: 575000000.00
MRNA balance_sheet (annual, 2022-12-31) — Receivables: 1685000000.00
MRNA income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 5416000000.00
MRNA income_statement (annual, 2022-12-31) — Reconciled Depreciation: 348000000.00
MRNA cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -3329000000.00
MRNA income_statement (annual, 2022-12-31) — Research And Development: 3295000000.00
MRNA balance_sheet (annual, 2022-12-31) — Retained Earnings: 18320000000.00
MRNA cash_flow (annual, 2022-12-31) — Sale Of Investment: 6699000000.00
MRNA income_statement (annual, 2022-12-31) — Selling General And Administration: 1132000000.00
MRNA balance_sheet (annual, 2022-12-31) — Share Issued: 385000000.00
MRNA cash_flow (annual, 2022-12-31) — Stock Based Compensation: 226000000.00
MRNA balance_sheet (annual, 2022-12-31) — Stockholders Equity: 19123000000.00
MRNA balance_sheet (annual, 2022-12-31) — Tangible Book Value: 19123000000.00
MRNA income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
MRNA income_statement (annual, 2022-12-31) — Tax Provision: 1213000000.00
MRNA income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.13
MRNA balance_sheet (annual, 2022-12-31) — Taxes Receivable: 150000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Assets: 25858000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Capitalization: 19123000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Debt: 1200000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 19123000000.00
MRNA income_statement (annual, 2022-12-31) — Total Expenses: 9455000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 6735000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 12427000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 1812000000.00
MRNA income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 9420000000.00
MRNA balance_sheet (annual, 2022-12-31) — Total Tax Payable: 48000000.00
MRNA income_statement (annual, 2022-12-31) — Total Unusual Items: -20000000.00
MRNA income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -20000000.00
MRNA balance_sheet (annual, 2022-12-31) — Work In Process: 205000000.00
MRNA balance_sheet (annual, 2022-12-31) — Working Capital: 8508000000.00
MRNA income_statement (annual, 2023-12-31) — +Operating Expense: 6300000000.00
MRNA income_statement (annual, 2023-12-31) — +Total Revenue: 6754000000.00
MRNA balance_sheet (annual, 2023-12-31) — Accounts Payable: 520000000.00
MRNA balance_sheet (annual, 2023-12-31) — Accounts Receivable: 892000000.00
MRNA balance_sheet (annual, 2023-12-31) — Accrued Interest Receivable: 59000000.00
MRNA balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -433000000.00
MRNA balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 371000000.00
MRNA balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -692000000.00
MRNA cash_flow (annual, 2023-12-31) — Amortization Of Securities: -61000000.00
MRNA balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 4677000000.00
MRNA income_statement (annual, 2023-12-31) — Basic Average Shares: 382000000.00
MRNA income_statement (annual, 2023-12-31) — Basic EPS: -12.33
MRNA cash_flow (annual, 2023-12-31) — Beginning Cash Position: 3217000000.00
MRNA balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 0.00
MRNA cash_flow (annual, 2023-12-31) — Capital Expenditure: -707000000.00
MRNA balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1243000000.00
MRNA balance_sheet (annual, 2023-12-31) — Capital Stock: 0.00
MRNA balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 2907000000.00
MRNA balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 8604000000.00
MRNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -1377000000.00
MRNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 4206000000.00
MRNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -3118000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Account Payable: 13000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -340000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Income Tax Payable: 15000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Inventory: 747000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -605000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 639000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -2060000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Payable: 13000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -327000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 1802000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Receivables: 493000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Tax Payable: 15000000.00
MRNA cash_flow (annual, 2023-12-31) — Change In Working Capital: 689000000.00
MRNA cash_flow (annual, 2023-12-31) — Changes In Account Receivables: 493000000.00
MRNA cash_flow (annual, 2023-12-31) — Changes In Cash: -289000000.00
MRNA balance_sheet (annual, 2023-12-31) — Common Stock: 0.00
MRNA balance_sheet (annual, 2023-12-31) — Common Stock Equity: 13854000000.00
MRNA cash_flow (annual, 2023-12-31) — Common Stock Issuance: 46000000.00
MRNA cash_flow (annual, 2023-12-31) — Common Stock Payments: -1153000000.00
MRNA balance_sheet (annual, 2023-12-31) — Construction In Progress: 860000000.00
MRNA income_statement (annual, 2023-12-31) — Cost Of Revenue: 4693000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 997000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Assets: 10325000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 25000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 25000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 568000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 568000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Liabilities: 3015000000.00
MRNA balance_sheet (annual, 2023-12-31) — Current Provisions: 556000000.00
MRNA cash_flow (annual, 2023-12-31) — Deferred Income Tax: 828000000.00
MRNA cash_flow (annual, 2023-12-31) — Deferred Tax: 828000000.00
MRNA cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 621000000.00
MRNA cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 621000000.00
MRNA income_statement (annual, 2023-12-31) — Diluted Average Shares: 382000000.00
MRNA income_statement (annual, 2023-12-31) — Diluted EPS: -12.33
MRNA income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — EBIT: -4239000000.00
MRNA income_statement (annual, 2023-12-31) — EBITDA: -3618000000.00
MRNA cash_flow (annual, 2023-12-31) — Earnings Losses From Equity Investments: 35000000.00
MRNA cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 0.00
MRNA cash_flow (annual, 2023-12-31) — End Cash Position: 2928000000.00
MRNA cash_flow (annual, 2023-12-31) — Financing Cash Flow: -1377000000.00
MRNA balance_sheet (annual, 2023-12-31) — Finished Goods: 24000000.00
MRNA cash_flow (annual, 2023-12-31) — Free Cash Flow: -3825000000.00
MRNA income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -72000000.00
MRNA balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -123000000.00
MRNA balance_sheet (annual, 2023-12-31) — Goodwill: 52000000.00
MRNA balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 96000000.00
MRNA balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 1584000000.00
MRNA balance_sheet (annual, 2023-12-31) — Gross PPE: 3091000000.00
MRNA income_statement (annual, 2023-12-31) — Gross Profit: 2061000000.00
MRNA balance_sheet (annual, 2023-12-31) — Income Tax Payable: 63000000.00
MRNA income_statement (annual, 2023-12-31) — Interest Expense: 38000000.00
MRNA income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 38000000.00
MRNA income_statement (annual, 2023-12-31) — Interest Income: 421000000.00
MRNA income_statement (annual, 2023-12-31) — Interest Income Non Operating: 421000000.00
MRNA cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 39000000.00
MRNA balance_sheet (annual, 2023-12-31) — Inventory: 202000000.00
MRNA balance_sheet (annual, 2023-12-31) — Invested Capital: 13854000000.00
MRNA cash_flow (annual, 2023-12-31) — Investing Cash Flow: 4206000000.00
MRNA balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 4677000000.00
MRNA balance_sheet (annual, 2023-12-31) — Investments And Advances: 4743000000.00
MRNA cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 46000000.00
MRNA cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
MRNA balance_sheet (annual, 2023-12-31) — Land And Improvements: 22000000.00
MRNA balance_sheet (annual, 2023-12-31) — Leases: 522000000.00
MRNA balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1218000000.00
MRNA balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 1218000000.00
MRNA cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 0.00
MRNA cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
MRNA balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 66000000.00
MRNA balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 100000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -85000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 46000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -4714000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -4714000000.00
MRNA income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -4714000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (annual, 2023-12-31) — Net Interest Income: 421000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 4998000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -270000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -270000000.00
MRNA income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 421000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -1153000000.00
MRNA cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -23000000.00
MRNA balance_sheet (annual, 2023-12-31) — Net PPE: 2658000000.00
MRNA cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -707000000.00
MRNA balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 13758000000.00
MRNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 83000000.00
MRNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 83000000.00
MRNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 342000000.00
MRNA income_statement (annual, 2023-12-31) — Normalized EBITDA: -3618000000.00
MRNA income_statement (annual, 2023-12-31) — Normalized Income: -4714000000.00
MRNA balance_sheet (annual, 2023-12-31) — Notes Receivable: 0.00
MRNA cash_flow (annual, 2023-12-31) — Operating Cash Flow: -3118000000.00
MRNA cash_flow (annual, 2023-12-31) — Operating Gains Losses: 35000000.00
MRNA income_statement (annual, 2023-12-31) — Operating Income: -4239000000.00
MRNA income_statement (annual, 2023-12-31) — Operating Revenue: 8203000000.00
MRNA balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 382000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Current Assets: 88000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 41000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -123000000.00
MRNA income_statement (annual, 2023-12-31) — Other Income Expense: -124000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 44000000.00
MRNA cash_flow (annual, 2023-12-31) — Other Non Cash Items: 7000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 181000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 21000000.00
MRNA income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -124000000.00
MRNA income_statement (annual, 2023-12-31) — Other Operating Expenses: -94000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Properties: 1587000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Receivables: 61000000.00
MRNA balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 5697000000.00
MRNA balance_sheet (annual, 2023-12-31) — Payables: 583000000.00
MRNA balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 1580000000.00
MRNA balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 245000000.00
MRNA balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
MRNA balance_sheet (annual, 2023-12-31) — Prepaid Assets: 350000000.00
MRNA income_statement (annual, 2023-12-31) — Pretax Income: -3942000000.00
MRNA cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 46000000.00
MRNA balance_sheet (annual, 2023-12-31) — Properties: 0.00
MRNA cash_flow (annual, 2023-12-31) — Purchase Of Business: -85000000.00
MRNA cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: 0.00
MRNA cash_flow (annual, 2023-12-31) — Purchase Of Investment: -3783000000.00
MRNA cash_flow (annual, 2023-12-31) — Purchase Of PPE: -707000000.00
MRNA balance_sheet (annual, 2023-12-31) — Raw Materials: 163000000.00
MRNA balance_sheet (annual, 2023-12-31) — Receivables: 1081000000.00
MRNA income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 4693000000.00
MRNA income_statement (annual, 2023-12-31) — Reconciled Depreciation: 621000000.00
MRNA cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
MRNA cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -1153000000.00
MRNA income_statement (annual, 2023-12-31) — Research And Development: 4845000000.00
MRNA balance_sheet (annual, 2023-12-31) — Retained Earnings: 13606000000.00
MRNA cash_flow (annual, 2023-12-31) — Sale Of Investment: 8781000000.00
MRNA income_statement (annual, 2023-12-31) — Selling General And Administration: 1549000000.00
MRNA balance_sheet (annual, 2023-12-31) — Share Issued: 382000000.00
MRNA cash_flow (annual, 2023-12-31) — Stock Based Compensation: 305000000.00
MRNA balance_sheet (annual, 2023-12-31) — Stockholders Equity: 13854000000.00
MRNA balance_sheet (annual, 2023-12-31) — Tangible Book Value: 13758000000.00
MRNA income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
MRNA income_statement (annual, 2023-12-31) — Tax Provision: 772000000.00
MRNA income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.21
MRNA balance_sheet (annual, 2023-12-31) — Taxes Receivable: 69000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Assets: 18426000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Capitalization: 13854000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Debt: 1243000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 13854000000.00
MRNA income_statement (annual, 2023-12-31) — Total Expenses: 10993000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 4572000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 8101000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 1557000000.00
MRNA income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -4239000000.00
MRNA balance_sheet (annual, 2023-12-31) — Total Tax Payable: 63000000.00
MRNA income_statement (annual, 2023-12-31) — Total Unusual Items: -72000000.00
MRNA income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -72000000.00
MRNA balance_sheet (annual, 2023-12-31) — Tradeand Other Payables Non Current: 235000000.00
MRNA balance_sheet (annual, 2023-12-31) — Work In Process: 15000000.00
MRNA balance_sheet (annual, 2023-12-31) — Working Capital: 7310000000.00
MRNA cash_flow (quarterly, 2024-09-30) — Change In Income Tax Payable: -2000000.00
MRNA cash_flow (quarterly, 2024-09-30) — Change In Tax Payable: -2000000.00
MRNA cash_flow (quarterly, 2024-09-30) — Common Stock Payments: 0.00
MRNA cash_flow (quarterly, 2024-09-30) — Deferred Income Tax: 0.00
MRNA cash_flow (quarterly, 2024-09-30) — Deferred Tax: 0.00
MRNA balance_sheet (quarterly, 2024-09-30) — Income Tax Payable: 4000000.00
MRNA cash_flow (quarterly, 2024-09-30) — Net Business Purchase And Sale: 0.00
MRNA cash_flow (quarterly, 2024-09-30) — Purchase Of Business: 0.00
MRNA cash_flow (quarterly, 2024-09-30) — Repurchase Of Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 4000000.00
MRNA income_statement (annual, 2024-12-31) — +Operating Expense: 5680000000.00
MRNA income_statement (annual, 2024-12-31) — +Total Revenue: 3199000000.00
MRNA balance_sheet (annual, 2024-12-31) — Accounts Payable: 405000000.00
MRNA balance_sheet (annual, 2024-12-31) — Accounts Receivable: 358000000.00
MRNA balance_sheet (annual, 2024-12-31) — Accrued Interest Receivable: 59000000.00
MRNA balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -527000000.00
MRNA balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 866000000.00
MRNA balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -340000000.00
MRNA cash_flow (annual, 2024-12-31) — Amortization Of Securities: -95000000.00
MRNA balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 2494000000.00
MRNA income_statement (annual, 2024-12-31) — Basic Average Shares: 384000000.00
MRNA income_statement (annual, 2024-12-31) — Basic EPS: -9.28
MRNA cash_flow (annual, 2024-12-31) — Beginning Cash Position: 2928000000.00
MRNA balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 743000000.00
MRNA cash_flow (annual, 2024-12-31) — Capital Expenditure: -1051000000.00
MRNA balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 747000000.00
MRNA balance_sheet (annual, 2024-12-31) — Capital Stock: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 1927000000.00
MRNA balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 7025000000.00
MRNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 56000000.00
MRNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 1949000000.00
MRNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -3004000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Account Payable: -69000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -385000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Inventory: 83000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -53000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 106000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -439000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Payable: -69000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -454000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 145000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Receivables: 534000000.00
MRNA cash_flow (annual, 2024-12-31) — Change In Working Capital: -78000000.00
MRNA cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 534000000.00
MRNA cash_flow (annual, 2024-12-31) — Changes In Cash: -999000000.00
MRNA balance_sheet (annual, 2024-12-31) — Common Stock: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Common Stock Equity: 10901000000.00
MRNA cash_flow (annual, 2024-12-31) — Common Stock Issuance: 66000000.00
MRNA cash_flow (annual, 2024-12-31) — Common Stock Payments: 0.00
MRNA cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Construction In Progress: 1057000000.00
MRNA income_statement (annual, 2024-12-31) — Cost Of Revenue: 1464000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 745000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Assets: 8099000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 37000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 37000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 153000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 153000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Liabilities: 2206000000.00
MRNA balance_sheet (annual, 2024-12-31) — Current Provisions: 370000000.00
MRNA cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 189000000.00
MRNA cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 189000000.00
MRNA income_statement (annual, 2024-12-31) — Diluted Average Shares: 384000000.00
MRNA income_statement (annual, 2024-12-31) — Diluted EPS: -9.28
MRNA income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — EBIT: -3583000000.00
MRNA income_statement (annual, 2024-12-31) — EBITDA: -3394000000.00
MRNA cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: 52000000.00
MRNA cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 0.00
MRNA cash_flow (annual, 2024-12-31) — End Cash Position: 1929000000.00
MRNA cash_flow (annual, 2024-12-31) — Financing Cash Flow: 56000000.00
MRNA balance_sheet (annual, 2024-12-31) — Finished Goods: 28000000.00
MRNA cash_flow (annual, 2024-12-31) — Free Cash Flow: -4055000000.00
MRNA income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -56000000.00
MRNA income_statement (quarterly, 2024-12-31) — Gain On Sale Of Security: -9000000.00
MRNA balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -10000000.00
MRNA balance_sheet (annual, 2024-12-31) — Goodwill: 52000000.00
MRNA balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 92000000.00
MRNA balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 698000000.00
MRNA balance_sheet (annual, 2024-12-31) — Gross PPE: 3482000000.00
MRNA income_statement (annual, 2024-12-31) — Gross Profit: 1735000000.00
MRNA cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 197000000.00
MRNA balance_sheet (annual, 2024-12-31) — Income Tax Payable: 3000000.00
MRNA balance_sheet (quarterly, 2024-12-31) — Income Tax Payable: 3000000.00
MRNA income_statement (annual, 2024-12-31) — Interest Expense: 24000000.00
MRNA income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 24000000.00
MRNA income_statement (annual, 2024-12-31) — Interest Income: 425000000.00
MRNA income_statement (annual, 2024-12-31) — Interest Income Non Operating: 425000000.00
MRNA cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 24000000.00
MRNA balance_sheet (annual, 2024-12-31) — Inventory: 117000000.00
MRNA balance_sheet (annual, 2024-12-31) — Invested Capital: 10901000000.00
MRNA cash_flow (annual, 2024-12-31) — Investing Cash Flow: 1949000000.00
MRNA balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 2494000000.00
MRNA balance_sheet (annual, 2024-12-31) — Investments And Advances: 2508000000.00
MRNA cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 66000000.00
MRNA cash_flow (annual, 2024-12-31) — Issuance Of Debt: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Land And Improvements: 59000000.00
MRNA balance_sheet (annual, 2024-12-31) — Leases: 207000000.00
MRNA balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 710000000.00
MRNA balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 710000000.00
MRNA cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 0.00
MRNA cash_flow (annual, 2024-12-31) — Long Term Debt Payments: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 14000000.00
MRNA balance_sheet (quarterly, 2024-12-31) — Long Term Equity Investment: 14000000.00
MRNA balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 181000000.00
MRNA cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
MRNA cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 0.00
MRNA cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 66000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -3561000000.00
MRNA cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -3561000000.00
MRNA income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -3561000000.00
MRNA cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (annual, 2024-12-31) — Net Interest Income: 401000000.00
MRNA cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 3000000000.00